2024 Highlights

Valneva achieved several key milestones in 2024, including the Canadian and European approvals of Valneva’s single-shot chikungunya vaccine.

A specialty vaccine company

Chikungunya vaccine, VLA1553
Approvals in Canada (June), Europe (July) and UK (February 2025)

Recommendation granted by the U.S. Advisory Committee on Immunization Practices (ACIP) in February 2024.
Reported further Positive Pivotal Phase 3 Data in Adolescents in May 2024.
Expanded partnership with CEPI with a $41.3 Million Grant to Support Broader Access (July) and expanded Access to Asia with Serum Institute of India (December).
Submitted adolescent Label Extension Applications to EMA (September), Health Canada (September) and United States Food and Drug Administration (November). EMA announced a positive opinion in February 2025.
Positive Three-Year Antibody Persistence Data reported (December).

Lyme disease vaccine candidate, VLA15

Announced Primary Vaccination Series Completion (July).
Reported Further Positive Phase 2 Booster Results for Lyme Disease Vaccine Candidate (September).
Publication of Phase 2 Trials in the Lancet Infectious Diseases (June).

Augmented clinical pipeline with a leading tetravalent Shigella vaccine candidate and initiated Phase 2b trial; Granted Fast Track Designation by the FDA.
Extended partnership with the Coalition for Epidemic Preparedness (CEPI) via a new $41.3m grant and signed exclusive license agreement with the Serum Institute of India (SII) for Asia. Advanced novel Zika vaccine candidate into Phase 1 clinical development.

Finalized new $32.8 million IXIARO^® supply contract with the U.S. Department of Defense in January 2025.
Product sales revenue reached €163.3 million for the year ended December 31, 2024 compared to €144.6 million in the same period of 2023, an increase of 13%.